NKTR
Price
$24.79
Change
-$0.15 (-0.60%)
Updated
Jul 21 closing price
Capitalization
428.88M
16 days until earnings call
VYNE
Price
$1.21
Change
+$0.05 (+4.31%)
Updated
Jul 21 closing price
Capitalization
20.16M
Interact to see
Advertisement

NKTR vs VYNE

Header iconNKTR vs VYNE Comparison
Open Charts NKTR vs VYNEBanner chart's image
Nektar Therapeutics
Price$24.79
Change-$0.15 (-0.60%)
Volume$598K
Capitalization428.88M
VYNE Therapeutics
Price$1.21
Change+$0.05 (+4.31%)
Volume$1.08M
Capitalization20.16M
NKTR vs VYNE Comparison Chart in %
Loading...
NKTR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NKTR vs. VYNE commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTR is a Hold and VYNE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (NKTR: $24.79 vs. VYNE: $1.21)
Brand notoriety: NKTR: Notable vs. VYNE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NKTR: 24% vs. VYNE: 133%
Market capitalization -- NKTR: $428.88M vs. VYNE: $20.16M
NKTR [@Biotechnology] is valued at $428.88M. VYNE’s [@Biotechnology] market capitalization is $20.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NKTR’s FA Score shows that 0 FA rating(s) are green whileVYNE’s FA Score has 1 green FA rating(s).

  • NKTR’s FA Score: 0 green, 5 red.
  • VYNE’s FA Score: 1 green, 4 red.
According to our system of comparison, VYNE is a better buy in the long-term than NKTR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NKTR’s TA Score shows that 6 TA indicator(s) are bullish while VYNE’s TA Score has 3 bullish TA indicator(s).

  • NKTR’s TA Score: 6 bullish, 4 bearish.
  • VYNE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, NKTR is a better buy in the short-term than VYNE.

Price Growth

NKTR (@Biotechnology) experienced а +1.56% price change this week, while VYNE (@Biotechnology) price change was -9.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +15.71%, and the average quarterly price growth was +33.77%.

Reported Earning Dates

NKTR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NKTR($429M) has a higher market cap than VYNE($20.2M). NKTR YTD gains are higher at: 77.706 vs. VYNE (-63.881). VYNE has higher annual earnings (EBITDA): -45.44M vs. NKTR (-97.97M). NKTR has more cash in the bank: 219M vs. VYNE (50.3M). VYNE has less debt than NKTR: VYNE (63K) vs NKTR (100M). NKTR has higher revenues than VYNE: NKTR (87.2M) vs VYNE (605K).
NKTRVYNENKTR / VYNE
Capitalization429M20.2M2,124%
EBITDA-97.97M-45.44M216%
Gain YTD77.706-63.881-122%
P/E RatioN/A0.71-
Revenue87.2M605K14,413%
Total Cash219M50.3M435%
Total Debt100M63K158,730%
FUNDAMENTALS RATINGS
NKTR vs VYNE: Fundamental Ratings
NKTR
VYNE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3465
P/E GROWTH RATING
1..100
831
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYNE's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for NKTR (84) in the Biotechnology industry. This means that VYNE’s stock grew somewhat faster than NKTR’s over the last 12 months.

VYNE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NKTR (100) in the Biotechnology industry. This means that VYNE’s stock grew similarly to NKTR’s over the last 12 months.

VYNE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as NKTR (99) in the Biotechnology industry. This means that VYNE’s stock grew similarly to NKTR’s over the last 12 months.

NKTR's Price Growth Rating (34) in the Biotechnology industry is in the same range as VYNE (65) in the Pharmaceuticals Major industry. This means that NKTR’s stock grew similarly to VYNE’s over the last 12 months.

VYNE's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for NKTR (83) in the Biotechnology industry. This means that VYNE’s stock grew significantly faster than NKTR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NKTRVYNE
RSI
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
71%
Bearish Trend 4 days ago
82%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 13 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
NKTR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SYNX1.770.04
+2.31%
Silynxcom Ltd
PRKS48.640.67
+1.40%
United Parks & Resorts
LANV2.430.02
+0.83%
Lanvin Group Holdings Limited
EOLS9.22-0.12
-1.28%
Evolus
DVN32.35-0.50
-1.52%
Devon Energy Corp

NKTR and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTR has been loosely correlated with CRNX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTR
1D Price
Change %
NKTR100%
-0.60%
CRNX - NKTR
43%
Loosely correlated
-0.51%
YMAB - NKTR
41%
Loosely correlated
+0.46%
AMLX - NKTR
39%
Loosely correlated
-1.56%
ARCT - NKTR
38%
Loosely correlated
+2.15%
ABCL - NKTR
38%
Loosely correlated
+15.21%
More

VYNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with EYPT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
+4.31%
EYPT - VYNE
34%
Loosely correlated
+2.33%
SYRE - VYNE
34%
Loosely correlated
+0.37%
GLTO - VYNE
30%
Poorly correlated
+0.23%
ARCT - VYNE
30%
Poorly correlated
+2.15%
NKTR - VYNE
30%
Poorly correlated
-0.60%
More